Market Overview

BofA: Scotts Miracle-Gro Faces Too Many Near-Term Risks

Share:
BofA: Scotts Miracle-Gro Faces Too Many Near-Term Risks
Related SMG
Pot Stocks, ETFs, Top News And Data From The Cannabis Industry This Week
Pot Stocks, ETFs, Top News And Data From The Cannabis Industry This Week

Scotts Miracle-Gro Co (NYSE: SMG)'s second-quarter report convinced Bank of America Merrill Lynch to switch from a bullish to a bearish stance on the lawn and garden company. 

The Analyst

BofA's Christopher Carey downgraded Scotts Miracle-Gro rating from Buy to Underperform with a price target slashed from $100 to $80.

The Thesis

Scotts Miracle-Gro's Q2 print shows multiple near-term risks that put an end to BofA's bullish thesis, Carey said in the downgrade note. (See the analyst's track record here.) They are: 

  • The company faces an "atypically" cold start to the garden season exacerbated by tight inventory management at the retail channel.
  • Higher transportation costs resulted in an 8-percent profit miss.
  • A reduction in Scotts' fiscal 2018 guidance is expected in its June investor update.
  • Margin headwinds for fiscal 2019 include commodity prices, distribution costs and the reversal of employee comp.

The long-term setup for Scotts Miracle-Gro remains unchanged, Carey said. The company is still a leader in the hydroponics space, which will likely see outsized growth versus its core business, he said. The U.S. consumer business will contribute a "stable base" of modest earnings growth and strong free cash flow generation, the analyst said. 

Scotts Miracle-Gro's near-term headwinds outweigh the longer-term picture, according to BofA. 

The firm's revised $80 price target for Scotts is based on a 17x multiple on calendar 2019 EPS, down from a prior 22x multiple.

A premium multiple is no longer justified, as there are few near term catalysts; M&A deals have already been announced; and the visibility on a turnaround in Hawthorne is still low, Carey said. 

Price Action

Scotts Miracle-Gro shares were down 7.85 percent at $77.97 at the time of publication Wednesday afternoon.  

Related Links:

Benzinga's Top Upgrades, Downgrades For May 2, 2018

Pot Stocks, ETFs, Top News And Data From The Cannabis Industry This Week

Latest Ratings for SMG

DateFirmActionFromTo
Aug 2018JP MorganMaintainsUnderweightUnderweight
Aug 2018Bank of AmericaMaintainsUnderperformUnderperform
Jul 2018Bank of AmericaMaintainsUnderperformUnderperform

View More Analyst Ratings for SMG
View the Latest Analyst Ratings

Posted-In: Bank of America Merrill Lynch Christopher Carey home and garden retailAnalyst Color Downgrades Price Target Analyst Ratings Best of Benzinga

 

Related Articles (SMG)

View Comments and Join the Discussion!

Meritor Q2 Earnings Preview

Berry Plastics Group Q2 Earnings Outlook